AbbVie (ABBV) : The value of composite uptick trades was $51.17 million, whereas, the value of composite downtick trades was $99.9 million. The uptick to downtick ratio stood at 0.51 with a negative money flow of ($48.74) Million during Mondays trading session. The block trades money flow was negative ($47.3 million).The uptick to the downtick ratio of 0.1 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $5.26 million. The transaction of the trades on downticks amounted to $52.57 million, which confirms investors selling on the strength of price. AbbVie (ABBV) gained 24 cents at $63.56, an increase of 0.38% over the previous days close.
AbbVie Inc. is up 7.08% in the last 3-month period. Year-to-Date the stock performance stands at 10.42%. AbbVie Inc. has dropped 0.36% in the last five trading days, however, the shares have posted positive gains of 5.28% in the last 4 weeks. In a related news, The Securities and Exchange Commission has divulged that Schumacher Laura J, Officer (Executive Vice President) of AbbVie Inc., had unloaded 186,106 shares at an average price of $60.07 in a transaction dated on June 24, 2016. The total value of the transaction was worth $11,179,387.
AbbVie (NYSE:ABBV): stock turned positive on Monday. Though the stock opened at $63.23, the bulls momentum made the stock top out at $63.77 level for the day. The stock recorded a low of $63.18 and closed the trading day at $63.56, in the green by 0.38%. The total traded volume for the day was 6,384,755. The stock had closed at $63.32 in the previous days trading.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.